Association of Leukocyte Telomere Length With Mortality Among Adult Participants in 3 Longitudinal Studies.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
05 02 2020
05 02 2020
Historique:
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
26
8
2020
Statut:
epublish
Résumé
Leukocyte telomere length (LTL) is a trait associated with risk of cardiovascular disease and cancer, the 2 major disease categories that largely define longevity in the United States. However, it remains unclear whether LTL is associated with the human life span. To examine whether LTL is associated with the life span of contemporary humans. This cohort study included 3259 adults of European ancestry from the Cardiovascular Health Study (CHS), Framingham Heart Study (FHS), and Women's Health Initiative (WHI). Leukocyte telomere length was measured in 1992 and 1997 in the CHS, from 1995 to 1998 in the FHS, and from 1993 to 1998 in the WHI. Data analysis was conducted from February 2017 to December 2019. Death and LTL, measured by Southern blots of the terminal restriction fragments, were the main outcomes. Cause of death was adjudicated by end point committees. The analyzed sample included 3259 participants (2342 [71.9%] women), with a median (range) age of 69.0 (50.0-98.0) years at blood collection. The median (range) follow-up until death was 10.9 (0.2-23.0) years in CHS, 19.7 (3.4-23.0) years in FHS, and 16.6 (0.5-20.0) years in WHI. During follow-up, there were 1525 deaths (482 [31.6%] of cardiovascular disease; 373 [24.5%] of cancer, and 670 [43.9%] of other or unknown causes). Short LTL, expressed in residual LTL, was associated with increased mortality risk. Overall, the hazard ratio for all-cause mortality for a 1-kilobase decrease in LTL was 1.34 (95% CI, 1.21-1.47). This association was stronger for noncancer causes of death (cardiovascular death: hazard ratio, 1.28; 95% CI, 1.08-1.52; cancer: hazard ratio, 1.13; 95% CI, 0.93-1.36; and other causes: hazard ratio, 1.53; 95% CI, 1.32-1.77). The results of this study indicate that LTL is associated with a natural life span limit in contemporary humans.
Identifiants
pubmed: 32101305
pii: 2761863
doi: 10.1001/jamanetworkopen.2020.0023
pmc: PMC7137690
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e200023Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NICHD NIH HHS
ID : R03 HD050374
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG023629
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200036C
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL130114
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD071180
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85082
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG034424
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55222
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85086
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC25195
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG043352
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200800007C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85081
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85080
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL080295
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL116446
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85079
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85083
Pays : United States
Références
Leuk Res. 2015 Dec;39(12):1360-6
pubmed: 26520623
Hum Mol Genet. 2012 Dec 15;21(24):5385-94
pubmed: 23001564
Am J Epidemiol. 2008 Apr 1;167(7):799-806
pubmed: 18270372
Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2225-31
pubmed: 26249011
Nat Commun. 2013;4:1597
pubmed: 23511462
Cancer Res. 2014 Aug 1;74(15):4090-8
pubmed: 24853549
Oncotarget. 2017 Aug 7;8(37):62500-62507
pubmed: 28977964
Nature. 2017 Jun 28;546(7660):E11-E12
pubmed: 28658235
Am J Epidemiol. 2017 Jun 15;185(12):1317-1326
pubmed: 28459963
Aging Cell. 2013 Aug;12(4):615-21
pubmed: 23601089
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9293-8
pubmed: 20421499
Nat Protoc. 2010 Sep;5(9):1596-607
pubmed: 21085125
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1165-71
pubmed: 18388332
Science. 2018 Jun 29;360(6396):1459-1461
pubmed: 29954979
J Epidemiol. 2016;26(4):191-8
pubmed: 26639750
JAMA Oncol. 2017 May 1;3(5):636-651
pubmed: 28241208
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2439-46
pubmed: 25234236
Br J Cancer. 2015 Feb 17;112(4):769-76
pubmed: 25562437
Nature. 2016 Oct 13;538(7624):257-259
pubmed: 27706136
Pediatrics. 2016 Apr;137(4):
pubmed: 26969272
Br J Cancer. 2017 Aug 22;117(5):752-755
pubmed: 28742796
Nat Genet. 2013 Apr;45(4):422-7, 427e1-2
pubmed: 23535734
Am J Epidemiol. 2007 Jan 1;165(1):14-21
pubmed: 17043079
Circ Res. 2017 Jul 21;121(3):214-219
pubmed: 28515044
Public Health Rep. 2017 Nov/Dec;132(6):669-675
pubmed: 29091542
Aging Cell. 2007 Dec;6(6):769-74
pubmed: 17925004
Hum Mol Genet. 2016 Apr 15;25(8):1663-76
pubmed: 27008888
Int J Epidemiol. 2014 Jun;43(3):878-86
pubmed: 24425829
J Natl Cancer Inst. 2014 Sep 17;106(10):
pubmed: 25231748
Science. 2001 Feb 23;291(5508):1491-2
pubmed: 11234076
Aging Cell. 2019 Dec;18(6):e13017
pubmed: 31444995
Biometrics. 1978 Dec;34(4):541-54
pubmed: 373811
Epidemiology. 2015 Jul;26(4):528-35
pubmed: 26039272
Aging (Albany NY). 2017 Apr;9(4):1130-1142
pubmed: 28394764
J Dermatol Sci. 2015 Dec;80(3):168-74
pubmed: 26341697
Nature. 2017 Jun 28;546(7660):E13-E14
pubmed: 28658239